{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:05:25Z","timestamp":1774713925327,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,7,15]],"date-time":"2018-07-15T00:00:00Z","timestamp":1531612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Secondary hyperparathyroidism (<jats:styled-content style=\"fixed-case\">SHPT<\/jats:styled-content>), commonly encountered in patients receiving maintenance dialysis, is associated with numerous adverse outcomes, including mortality. Calcimimetics, agents that act on the calcium sensing receptor (Ca<jats:styled-content style=\"fixed-case\">SR<\/jats:styled-content>), were designed to overcome limitations in the use of vitamin D sterols to treat <jats:styled-content style=\"fixed-case\">SHPT<\/jats:styled-content>, and have demonstrated efficacy in reducing levels of <jats:styled-content style=\"fixed-case\">PTH<\/jats:styled-content> in randomized trials. Currently available calcimimetics include oral cinacalcet and the recently approved intravenously administered agent, etelcalcetide. While cinacalcet is an allosteric modulator of the Ca<jats:styled-content style=\"fixed-case\">SR<\/jats:styled-content>, etelcalcetide acts as a direct Ca<jats:styled-content style=\"fixed-case\">SR<\/jats:styled-content> agonist. Etelcalcetide's properties allow it to be administered intravenously thrice weekly at the end of a hemodialysis treatment session. Etelcalcetide has recently been shown to be more potent than cinacalcet in reducing <jats:styled-content style=\"fixed-case\">PTH<\/jats:styled-content> levels. However, etelcalcetide appears, like cinacalcet, to cause gastrointestinal intolerance. Additionally, etelcalcetide, which appears to reduce calcium substantially more than cinacalcet does, can prolong the <jats:styled-content style=\"fixed-case\">QT<\/jats:styled-content>c electrocardiographic interval. While etelcalcetide is very effective at reducing <jats:styled-content style=\"fixed-case\">PTH<\/jats:styled-content> levels, the current climate of dialysis cost containment in the United States may limit its widespread use. This review compares and contrasts the pharmacologic characteristics of cinacalcet and etelcalcetide, discusses the results of clinical trials involving these drugs, and posits implications for their use for clinical practice.<\/jats:p>","DOI":"10.1111\/sdi.12734","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T01:38:27Z","timestamp":1531705107000},"page":"440-444","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?"],"prefix":"10.1111","volume":"31","author":[{"given":"Keith E.","family":"Eidman","sequence":"first","affiliation":[{"name":"Division of Nephrology Hennepin Healthcare Systems Minneapolis MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Wetmore","sequence":"additional","affiliation":[{"name":"Division of Nephrology Hennepin Healthcare Systems Minneapolis MN USA"},{"name":"Chronic Disease Research Group Minneapolis Medical Research Foundation Minneapolis MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,7,15]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002009"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07304.x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06040710"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v31.pm9531176"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.suppl_10.10"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03270314"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03630509"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706130"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03940510"},{"key":"e_1_2_11_12_1","first-page":"CD005633","article-title":"Vitamin D compounds for people with chronic kidney disease requiring dialysis","volume":"4","author":"Palmer SC","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/366575a0"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.63.s85.22.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.36"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.115.098392"},{"key":"e_1_2_11_18_1","unstructured":"Sensipar\u00ae(cinacalcet) Tablets. (FDA package insert).2014.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021688s20_21_22lbl.pdf. Accessed June 11 2018."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948050-00002"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.314"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004060512"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19468"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.67139.x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3845"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000442754"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-015-0052-z"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013876"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm776"},{"key":"e_1_2_11_30_1","first-page":"520","article-title":"Effects of cinacalcet treatment on QT interval in hemodialysis patients","volume":"16","author":"Temiz G","year":"2016","journal-title":"Anatol J Cardiol"},{"key":"e_1_2_11_31_1","first-page":"272","article-title":"Cinacalcet may prolong the QT interval in patients on haemodialysis with secondary hyperparathyroidism","volume":"33","author":"Borrego\u2010Utiel FJ","year":"2013","journal-title":"Nefrologia"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205624"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fsdi.12734","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sdi.12734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T14:00:34Z","timestamp":1695045634000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/sdi.12734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,15]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/sdi.12734"],"URL":"https:\/\/doi.org\/10.1111\/sdi.12734","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,15]]},"assertion":[{"value":"2018-07-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}